No black box warning on record for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

As of the latest FDA labeling reviewed, Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide (OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypotension: Correct volume or salt depletion prior to administration. ( 5.2 ). • Monitor renal function and potassium in susceptible patients • Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase ( 5.3 ). • Observe for signs of fluid or electrolyte imbalance ( 5.6 ). • Exacerbation or activation of syste

No black box warning on record for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypotension: Correct volume or salt depletion prior to administration. ( 5.2 ). • Monitor renal function and potassium in susceptible patients • Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase ( 5.3 ). • Observe for signs of fluid or electrolyte imbalance ( 5.6 ). • Exacerbation or activation of syste

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Black Box Warning

No black box warning on record for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Other warnings & precautions

Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Black Box Warning

No black box warning on record for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Other warnings & precautions